The risk score's effectiveness was examined in 171 males from group 2 who had less (9 ng/ml) serum prostate-specific antigen levels, 226 of whom have been zero or most minor grade prostate cancer (7656 percent). This evidence concerns the gene KLK3 and prostate cancer.